Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment
A Phase 1b/2 Study of Hu5F9-G4 (Magrolimab) in Combination With Mogamulizumab in Relapsed/Refractory Treated T-Cell Lymphoma
Sponsor: National Cancer Institute (NCI)
Terminated
Drug supply issues
Other terminated trials from National Cancer Institute (NCI)
Other Mycosis Fungoides trials with similar outcome
A PHASE1/PHASE2 clinical study on Mycosis Fungoides and Recurrent Mycosis Fungoides, this trial is terminated or withdrawn. The trial is conducted by National Cancer Institute (NCI) and has accumulated 35 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
35 versions recorded-
Nov 2025 — Present [monthly]
Terminated PHASE1/PHASE2
-
Sep 2025 — Nov 2025 [monthly]
Terminated PHASE1/PHASE2
-
Nov 2024 — Sep 2025 [monthly]
Terminated PHASE1/PHASE2
Status: Active Not Recruiting → Terminated
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
▶ Show 30 earlier versions
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Apr 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE1_PHASE2
Status: Suspended → Recruiting
-
Dec 2023 — Jan 2024 [monthly]
Suspended PHASE1_PHASE2
-
Oct 2023 — Dec 2023 [monthly]
Suspended PHASE1_PHASE2
-
Sep 2023 — Oct 2023 [monthly]
Suspended PHASE1_PHASE2
Status: Recruiting → Suspended
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE1_PHASE2
-
May 2023 — Aug 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2022 — Feb 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE1_PHASE2
Status: Suspended → Recruiting
-
Sep 2022 — Nov 2022 [monthly]
Suspended PHASE1_PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Suspended PHASE1_PHASE2
-
Apr 2022 — Jul 2022 [monthly]
Suspended PHASE1_PHASE2
-
Feb 2022 — Apr 2022 [monthly]
Suspended PHASE1_PHASE2
Status: Recruiting → Suspended
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2021 — Jan 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE1_PHASE2
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Apr 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Oct 2020 — Dec 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .